Abstract
The pilocytic astrocytoma (PA), formerly referred to as juvenile pilocytic astrocytomas, are WHO grade I tumors, that commonly occur during childhood and rarely in the adult population. Genetic studies of this tumor report an activation of the MAPK / ERK pathway through changes in the BRAF gene.
The aim of this article is to report a series of atypical PA cases with an aggressive tumor biology that continue preserving the benign histology or transformed into high-grade gliomas, and review the biology, genetics, and emerging therapeutic possibilities for these cases. And finally expose controversies from the surgical treatment and complementary therapies.
References
Rodriguez EF, Scheithauer BW, Giannini C, Rynearson A, Cen L, Hoesley B ET A. PI3K/AKT pathway alterations are associated with clinically aggressive and histologically ana-plastic subsets of pilocytic Astrocytoma. Acta Neuropathol. 2011;121(3):407-20. http://dx.doi.org/10.1007/s00401-010-0784-9
Myung, Hwajin C, ChulKee P, Seung-Ki K, Se-Hoon L, Jae K. Analysis of the BRAFV600E Mutation in Central Nervous System Tumors. Transl Oncol. 2012;5(6):430-36. http://dx.doi.org/10.1593/tlo.12328
Hawkins CE, Walker E, Nequesha M. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low grade astro-cytoma. Clin Cancer Res.2011;17(14):4790-8. http://dx.doi. org/10.1158/1078-0432.CCR-11-0034
Horbinski C. To BRAF or Not to BRAF: Is That Even a Question Anymore?. J Neuropathol Exp Neurol. 2013;72(1):2-7. http://dx.doi.org/10.1097/NEN.0b013e318279f3db
Lin A, Rodriguez FJ, Karajannis MA, Williams SC, Legault G, Zagzag D, et al. Identification of 2 Novel KIAA1549:BRAF Fusion Variants. J Neuropathol Exp Neurol. 2012; 71:66-72.
Rodriguez FJ, Scheithauer BW, Burger PC, Jenkins S, Giannini C. Anaplasia in Pilocytic Astrocytoma Predicts Aggressive Behavior. American Am J Surg Pathol.2010;34(2):147-60. http://dx.doi.org/10.1097/PAS.0b013e3181c75238.
Johnson DR, Brown PD, Galanis E, Hammack JE. Pilocytic astrocytoma survival in adults: analysis of the Surveillance, epidemiology, and end results program of the National Cancer Institute. J Neurooncol. 2012;108(1):187-93. http://dx.doi.org/10.1007/s11060-012-0829-0
Bilginer B, Narin F, karlioguz K, Uzun S, Soylemezoglu F, Akalan N. Benign cerebellar pilocytic astrocytomas in children. Turk Neurosurg. 2011; 21(1):22-26.
Hawkins C, Walker E, Mohamed N, Zhang C, Jacob K, Shirin-ian M, et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low grade astrocytoma. Clin Cancer Res. 2011;17(14):4790-8. http://dx.doi.org/10.1158/1078-0432.CCR-11-0034
Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Mende CH, et al. Analysis of BRAF V600E mutation in 1320 nervous system tumorsreveals high mutation frequencies in pleomor-phic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121(3):397-405. http://dx.doi.org/10.1007/s00401-011-0802-6
AlShakweer W, Alwelaie Y, Mankung AM, Graeber MB. Bone marrow-derived microglia in pilocyticastrocytoma. Front Biosci (Elite Ed). 2011; 3:371-79.
Ishkanian A, Laperriere NJ, Xu Millar BA, Payne D, Mason W. Upfront Observation versus radiation for adult pilocytic astrocytoma. Cancer. 2011;117(17):4070-79. http://dx.doi.org/10.1002/cncr.25988
Mansur DB , Rubin JB , Kidd EA , King AA , Hollander AS , Smyth MD, et al. Radiation therapy for pilocyticastrocytomas of childhood. Int J Radiat Oncol Biol Phys.2011;79(3):829-34. http://dx.doi.org/10.1016/jijrobp.2009.11.015
Lizarraga KJ, Gorgulho A, Lee SP, Rauscher G, Selch MT, DeSalles AF. Stereotactic radiation therapy for progressive residualpilocytic astrocytomas. J Neurooncol. 2012;109(1):129-35. http://dx.doi.org/10.1007/s11060-012-0877
McLendon RE, Adesina AM. Pathology of Expansile Astrocytomas [Internet]. Updated: Sep 15, 2015. Disponible: emedicine.medscape.com/article/1780937-overview
Kleinschmidt BK, Aisner DL, Birks DK, Foreman NK. Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol. 2013;37(5):685-98. http://dx.doi.org/10.1097/PAS.0b013e31827f9c5e
Robinson GW, Orr BA, Gajjar A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer. 2014; 14:258-62.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.